 Braxia Scientific Corp released its quarterly and year-end results showing the company heading into its next fiscal year with C11.1 million in cash. For the year ended March 31, 2021, Braxia reported revenue of 1,008,372 and a gross margin of 145,666, or 14.4, primarily derived from its network of ketamine clinics across Canada. 